Prevalence of Marginal Ulcer After PPPD and Preventive Effect of Proton Pump Inhibitor in Korea: A Prospective Multicenter Study

• Status: Not yet recruiting
• Trial end date: 2025-05-30
• Target enrollment: 0
• Participant gender: All

Summary

This research is to determine which medication, Esmesol (PPI) or Placebo works best at reducing the chance that a patient will get an marginal ulcer after pancreaticoduodenectomy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gangnam Severance Hospital

Criteria

Inclusion Criteria:

• Subject is age ≥ 19 years Patient meets the criteria for Open/MIS PPPD Females only:

Patient is willing to take a urine pregnancy test

Exclusion Criteria:

• Subject allergic to ESMESOL Patient receiving antifungal (i.e. ketoconazole or itraconazole) Hepatic insufficiency History of Crohns disease History of Zollinger-Ellison disease Patient received an investigational drug within 30 days of enrollment Previous Gastric Surgery HX